Genprex
Genprex, Inc. is a clinical-stage gene therapy company dedicated to developing innovative therapies for cancer and diabetes. They focus on leveraging proprietary technology platforms, including non-viral vectors, to create life-changing treatments. The company is actively involved in clinical trials, research collaborations, and advancing gene therapy technologies, with a strong commitment to reprogramming the course of lung cancer and other cancers, as well as addressing diabetes.
Industries
Nr. of Employees
small (1-50)
Products
Systemic plasmid DNA therapy using nonviral nanoparticle delivery (tumor suppressor replacement)
A systemically administered plasmid DNA therapeutic formulated in nonviral nanoparticles intended to restore tumor suppressor activity for oncology indications and to be evaluated in combination with targeted and immune therapies.
Gene-based therapy candidate for glucose regulation
A gene therapy approach developed to stabilize or improve glucose control in type 1 and type 2 diabetes, supported by preclinical data and academic licensing.
Early-stage investigational gene therapy programs
Preclinical and early clinical gene therapy candidates targeting oncology and other indications to expand the development pipeline and diversify indications.
Reqorsa® Gene Therapy
The Company’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Oncoprex® Delivery System
Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.
GPX-002
Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
Systemic plasmid DNA therapy using nonviral nanoparticle delivery (tumor suppressor replacement)
A systemically administered plasmid DNA therapeutic formulated in nonviral nanoparticles intended to restore tumor suppressor activity for oncology indications and to be evaluated in combination with targeted and immune therapies.
Gene-based therapy candidate for glucose regulation
A gene therapy approach developed to stabilize or improve glucose control in type 1 and type 2 diabetes, supported by preclinical data and academic licensing.
Early-stage investigational gene therapy programs
Preclinical and early clinical gene therapy candidates targeting oncology and other indications to expand the development pipeline and diversify indications.
Reqorsa® Gene Therapy
The Company’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Oncoprex® Delivery System
Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.
GPX-002
Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
Services
Structured sponsored research agreements with academic centers to support preclinical and translational studies for gene therapy programs.
In-licensing and option agreements to acquire additional gene therapy technologies and enter partnerships to expand program scope and indications.
Structured sponsored research agreements with academic centers to support preclinical and translational studies for gene therapy programs.
In-licensing and option agreements to acquire additional gene therapy technologies and enter partnerships to expand program scope and indications.
Expertise Areas
- Gene therapy development
- Nonviral nucleic acid delivery
- Oncology therapeutics (NSCLC, glioblastoma, small cell lung cancer)
- Gene-based metabolic therapeutics (diabetes)
Key Technologies
- Nonviral nanoparticle delivery
- Plasmid DNA therapeutics
- Tumor suppressor gene replacement
- Immunogene therapy approaches